EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 302 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Family Brings Joy & Raises Money With Their Extravagant Christmas Light... December 11, 2021 Woman Suffers Seizure And Dies After Making Fatal Error With Her... May 3, 2019 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... June 13, 2025 Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease... July 21, 2025 Load more HOT NEWS Researchers Find New, Effective Tools to Determine Breast Cancer Risk Using... Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... 10 Tips for Healthy Eating After Cancer Treatment Man Offers Free Lawn Mowing Service To Elderly And Veterans
